Shares of biotech company Atea Pharmaceuticals (NASDAQ:AVIR) are up 16.8% as of mid-Monday, although not in response to news from or about the company. Rather, a U.S. Food and Drug Administration advisory panel’s recent recommendation against COVID-19 vaccine boosters (for most people) bodes well for Atea’s trial of a drug aimed at treating the disease once a patient is infected.
Investors are simply connecting the dots.
On Friday, a panel that makes drug approval and rejection recommendations to the FDA advised the agency that there would be no significant benefit in administering so-called booster vaccine injections for most people who have already been fully inoculated by the vaccine jointly made by Pfizer and BioNTech.
The decision does not apply to the Moderna and Johnson & Johnson COVID-19 vaccines. But, given the similar efficacies of all three vaccine options, the panel’s viewpoint suggests that booster injections of J&J’s and Moderna’s vaccines may also make little impact.
While the advisory panel’s decision is nonbinding, the FDA typically follows its panels’ advice.
The lack of booster injections for most of the nation’s population may or may not facilitate the continued spread of the disease. But investors are broadly betting that it will. Atea Pharmaceuticals is developing AT-527 as an orally administered therapeutic for those who are already infected, which may become another much-needed weapon in the war on COVID-19. It won’t prevent transmission of the coronavirus, but it should curb the symptoms and risk for those who may end up contracting the disease.
The rationalization is sound enough. Investors were widely expecting the FDA’s advisory panel to recommend a third round of inoculations. Now with breakthrough cases seemingly more likely (and in patients that may not even realize they’ve been infected), COVID-19 may spread more than anticipated. The most symptomatic of these people must be treated somehow, and while therapies like Gilead Science‘s Remdesivir have their place, Remdesivir’s actual efficacy is in question. Other options can only help.
Updates on the phase 3 trial of AT-527 as a treatment for COVID-19, however, are still months away, and any approval of the drug would take much longer. Much can happen in the meantime, including the successful development of a pill-based coronavirus therapy from Merck or the aforementioned Pfizer.
Speculate on Atea if you must. Just bear in mind that’s all it is — a speculation. It’s hardly a buy-and-hold blue chip you can blindly tuck away for a few years.
This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.